PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Trial ID or NCT#
Status
Purpose
This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.
Official Title
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Eligibility Criteria
- - Women with histologically proven invasive stage I-II, node negative, hormone receptor positive, Her2 negative breast cancer, who received an Oncotype DX intermediate score (18-30) - ≥ 18 years of age at time of consent - Written informed consent
- - Insufficient tissue remaining for Mammaprint FFPE - Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria - Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Annabel Castaneda
650-498-7977
View on ClinicalTrials.gov